Invention Grant
- Patent Title: Protein sustained-release injectable formulation
-
Application No.: US15245767Application Date: 2016-08-24
-
Publication No.: US10093726B2Publication Date: 2018-10-09
- Inventor: Lutz Asmus , Michael Möller , Robert Gurny , John P. A. Grimshaw
- Applicant: ESBATech—a Novartis Company LLC
- Applicant Address: CH Schlieren
- Assignee: ESBATech, an Alcon Biomedical Research Unit LLC
- Current Assignee: ESBATech, an Alcon Biomedical Research Unit LLC
- Current Assignee Address: CH Schlieren
- Agent Jason J. Derry
- Main IPC: C07K16/22
- IPC: C07K16/22 ; A61K9/10 ; A61K47/34 ; A61K9/00 ; A61K39/395 ; C08J3/12 ; A61K9/16 ; A61K39/00
Abstract:
The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof.
Public/Granted literature
- US20160362483A1 PROTEIN SUSTAINED-RELEASE INJECTABLE FORMULATION Public/Granted day:2016-12-15
Information query
